Incyte Corporation (INCY)vsBeiGene, Ltd. (ONC)
INCY
Incyte Corporation
$127.10
-2.18%
HEALTHCARE · Cap: $23.42B
ONC
BeiGene, Ltd.
$322.08
-1.57%
HEALTHCARE · Cap: $34.29B
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 7% more annual revenue ($5.74B vs $5.36B). INCY leads profitability with a 26.7% profit margin vs 8.9%. INCY trades at a lower P/E of 16.6x. INCY earns a higher WallStSmart Score of 72/100 (B).
INCY
Strong Buy72
out of 100
Grade: B
ONC
Buy54
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+83.1%
Fair Value
$583.69
Current Price
$127.10
$456.59 discount
Margin of Safety
+81.1%
Fair Value
$1857.02
Current Price
$322.08
$1534.94 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 83.8% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Every $100 of equity generates 26 in profit
Keeps 27 of every $100 in revenue as profit
Attractively priced relative to earnings
Revenue surging 35.5% year-over-year
Earnings expanding 16971.0% YoY
Conservative balance sheet, low leverage
Areas to Watch
Expensive relative to growth rate
Premium valuation, high expectations priced in
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : INCY
The strongest argument for INCY centers on EPS Growth, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 26.7% and operating margin at 25.6%. Revenue growth of 20.9% demonstrates continued momentum.
Bull Case : ONC
The strongest argument for ONC centers on Revenue Growth, EPS Growth, Debt/Equity. Revenue growth of 35.5% demonstrates continued momentum.
Bear Case : INCY
The primary concerns for INCY are PEG Ratio.
Bear Case : ONC
The primary concerns for ONC are P/E Ratio, Altman Z-Score. A P/E of 74.6x leaves little room for execution misses.
Key Dynamics to Monitor
INCY profiles as a growth stock while ONC is a hypergrowth play — different risk/reward profiles.
INCY carries more volatility with a beta of 0.76 — expect wider price swings.
ONC is growing revenue faster at 35.5% — sustainability is the question.
INCY generates stronger free cash flow (359M), providing more financial flexibility.
Bottom Line
INCY scores higher overall (72/100 vs 54/100), backed by strong 26.7% margins and 20.9% revenue growth. ONC offers better value entry with a 81.1% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Incyte Corporation
HEALTHCARE · BIOTECHNOLOGY · USA
Incyte Corp is an American pharmaceutical company based in Alapocas, Delaware.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?